WNK2 and neoplasm: The proposed mechanism of anti-tumor activity is the inhibition of the downstream pathways of PI3K/Akt and mitogen-activated protein kinase (MAPK), induction of apoptosis and inhibition of proliferation, which results from inhibiting phosphorylation of these receptors by lapatinib [20].